The role of psychedelics in palliative care reconsidered: A case for psilocybin

Benjamin Kelmendi^{1

2}, Philip Corlett^{2

3}, Mohini Ranganathan^{2

4

5}, Cyril D'Souza^{2

3

4

5}, John H Krystal^{6

2

3

7

4

5}

Affiliations

¹ Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA ben.kelmendi@yale.edu.
² Departments of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
³ Departments of Neuroscience, Yale University School of Medicine, New Haven, CT, USA.
⁴ Schizophrenia and Neuropharmacology Research Group, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁵ Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
⁶ Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁷ Psychiatry Services, Yale-New Haven Hospital, New Haven, CT, USA.

Comment

Benjamin Kelmendi et al. J Psychopharmacol. 2016 Dec.

. 2016 Dec;30(12):1212-1214.

doi: 10.1177/0269881116675781.

Benjamin Kelmendi^{1

2}, Philip Corlett^{2

3}, Mohini Ranganathan^{2

4

5}, Cyril D'Souza^{2

3

4

5}, John H Krystal^{6

2

3

7

4

5}

¹ Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA ben.kelmendi@yale.edu.
² Departments of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
³ Departments of Neuroscience, Yale University School of Medicine, New Haven, CT, USA.
⁴ Schizophrenia and Neuropharmacology Research Group, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁵ Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA.
⁶ Clinical Neuroscience Division, Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.
⁷ Psychiatry Services, Yale-New Haven Hospital, New Haven, CT, USA.

No abstract available

Comment on

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Ross S, et al. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512. J Psychopharmacol. 2016. PMID: 27909164 Free PMC article. Clinical Trial.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.